BMS creates strategic leadership committee

Share this article:
Lamberto Andreotti
Lamberto Andreotti

Bristol-Myers Squibb (BMS) has created an executive committee of four, which will serve as the company's “senior strategy and decision-making body,” according to a BMS statement.

Lamberto Andreotti was promoted from EVP to president, and retained his role as COO. He was also tapped as a member of the executive committee, along with Elliott Sigal, EVP, chief scientific officer and president of R&D, Jean-Marc Huet, EVP and chief financial officer, and Jim Cornelius, chairman and CEO.

Tracy Furey, a BMS spokesperson, told Bloomberg that the committee will guide development of the company's experimental drugs, pursue small biotechnology companies and strike profit-sharing deals for new products.

In addition to establishing the committee, BMS announced several other promotions and appointments:

  • Anthony Hooper to president, Americas
  • Beatrice Cazala to president, global commercialization, and president, Europe
  • John Celentano to president, emerging markets and Asia-Pacific
  • Carlo De Notaristefani to president, technical operations and global support functions
  • Giovanni Caforio to SVP, global and US oncology

In a separate announcement, BMS said it will collaborate with two Japanese companies—Nissan Chemical Industries and Teijin Pharma Limited—to develop and commercialize NTC-801, an experimental treatment for abnormal heart rhythm, or atrial fibrillation.

Under the terms of the deal, which includes an up-front payment of $40 million and potential milestone payments in the future, BMS will obtain exclusive licensing rights to the drug worldwide, except in Japan.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, ...

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.